Cannabis and Pharma Marketing

Two regulated verticals, different playbooks

Cannabis and pharma are both heavily regulated. The regulations differ structurally. Cannabis is state-by-state legal in the US, federally illegal, banned by most major ad platforms. Pharma is federally regulated by FDA, allowed on major platforms with strict content rules.

Cannabis marketing

Channel landscape

Cannabis brands cannot run paid ads on Meta, TikTok, Google, or most mainstream ad networks. The available channels are:

• Cannabis-specific ad networks. Weedmaps, Leafly, MJBiz Daily, Cannabis Now. Limited reach but compliant.
• Out-of-home (OOH). Billboards and transit, where local rules permit.
• Print and direct mail. Cannabis-friendly publications.
• SEO and organic content. Heavy investment for many cannabis brands.
• Influencer marketing. Compliant influencers with age-gated content. Walks a thin line; rules vary by state.
• Email and SMS to opted-in consumers. Compliant when consent is clean.
• Direct retail and dispensary partnerships. The retailer relationship is the primary growth lever for most brands.

Compliance discipline

Age-gating on every digital asset. State-specific licensing checks. No medical claims unless backed by FDA approval (which essentially no cannabis brand has). No targeting minors. No targeting in states where the brand is not licensed.

Pharma marketing

Channel landscape

Pharma can advertise on most platforms with compliance review. Direct-to-consumer pharma advertising is legal in only the US and New Zealand globally. The available channels:

• Linear TV and CTV. Heavy DTC pharma investment; ISI (Important Safety Information) requirements drive long ad formats.
• Paid search. Google approves pharma brands with verification. Bidding on indication keywords ("treatment for X").
• Healthcare programmatic networks. HealthLine, WebMD, Sharecare. Audience-targeted to people researching specific conditions.
• HCP-targeted channels. Doximity, Sermo, Medscape — physician-only platforms.
• Disease awareness campaigns. Non-branded campaigns about a condition, which then point to branded content.

Compliance discipline

The big rules: fair balance of risk and benefit information (every claim of efficacy must be matched by safety information), no off-label promotion, ISI disclosure on every advertising asset, MLR (Medical/Legal/Regulatory) review on every piece. Influencer-led pharma marketing is increasingly common but requires careful disclosure.

What both verticals share

Long creative production cycles. Compliance review as the rate-limiter. Heavy investment in content marketing because paid channels are constrained or expensive. Strong reliance on owned channels (email, SMS, website) where compliance is easier to control.